Skip to main content

Advertisement

SpringerLink
Log in

The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis is a systemic disease that causes inflammation and joint destruction. As a result of pathological destruction in bone and cartilage, crosslinks in collagen are resorbed more rapidly. This causes a rise in circulating collagen crosslink levels and their urinary excretion. In RA, apart from the crosslink resorption at the site of inflamed joints, there may be increased resorption due to general bone loss associated with disease activity. The aim of this study was to evaluate the influence of therapy with infliximab on urinary excretion of pyridinoline (PYD) and deoxypyridinoline (DPYR) as a markers of collagen degradation and its correlation with clinical and biochemical parameters of disease activity. Seventeen patients with active rheumatoid arthritis treated with infliximab were recruited into the study. The therapy resulted in the reduction in the symptoms of RA and urinary excretion of PYD and DPYR. The urinary excretion of PYD correlated with a number of swollen joints, morning stiffness, CRP and ESR. The urinary excretion of DPYR correlated during infliximab therapy with the number of swollen and tender joints and morning stiffness. The measurement of urinary excretion of PYR and DPYR may give insight into bone metabolism and help us to better understand the actual changes in bone and cartilage caused by RA and its treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

DPYR:

Deoxypyridinoline

PYR:

Pyridinoline

RA:

Rheumatoid arthritis

References

  1. Sambrook PN (2000) The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis? J. Rheumatol 27:2541–2542

    CAS  Google Scholar 

  2. Joffe I, Epstein S (1991) Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 20:256–272

    Article  CAS  PubMed  Google Scholar 

  3. Taylor PC (2003) Anti-TNF alpha therapy for rheumatoid arthritis: an update. Intern Med 432:15–20

    Google Scholar 

  4. Cairns AP, Taggart AJ (2002) Anti-tumor necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 71:101–105

    PubMed  Google Scholar 

  5. Emery P (1994) Assessment of rheumatoid arthritis a clinician’s viewpoint. J Rheumatol (Suppl.) 42:20–24

    Google Scholar 

  6. Garnero P, Delmas PD (1996) New developments in biochemical markers for osteoporosis. Calcif Tissue Int 59 (Suppl. 1): 82–89

    Google Scholar 

  7. Seibel MJ, Duncan A, Robins SP (1989) Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 16:964–970

    CAS  PubMed  Google Scholar 

  8. Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ (1993) Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. Clin Rheumatol 12:240–244

    CAS  PubMed  Google Scholar 

  9. Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P (1994) Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 53:14–17

    CAS  PubMed  Google Scholar 

  10. Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27

    CAS  PubMed  Google Scholar 

  11. Ared WP, Dayer J-M (1990) Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305–315

    CAS  PubMed  Google Scholar 

  12. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z (1997) The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 40:1096–1105

    Google Scholar 

  13. Manicourt DH, Triki R, Fukuda K, Devogelaer J-P, Nagant de Deuxchaisnes C, Thonar EJ-MA (1993) Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis: relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 36:490–499

    CAS  PubMed  Google Scholar 

  14. Fujimoto D, Akiba K, Nakamura N (1977) Isolation and characterization of a fluorescent material in bovine Achilles tendon collagen. Biochem Biophys Res Commun 76:1124–1129

    CAS  PubMed  Google Scholar 

  15. Robins SP (1983) Cross-linking of collagen. Isolation, structural characterization and glycosylation of pyridinoline. Biochem J 215:167–173

    CAS  PubMed  Google Scholar 

  16. Ogawa T, Ono T, Tsuda M, Kawanishi Y (1982) A novel fluor in insoluble collagen: A crosslinking moiety in collagen molecule. Biochem Biophys Res Commun 107:1252–1257

    CAS  PubMed  Google Scholar 

  17. Eyre DR, Wu JJ, Woods PE (1991) The cartilage collagens: Structural and metabolic studies. J Rheumatol 18 (Suppl. 27):49–51

    Google Scholar 

  18. Eyre DR, Koob TJ, Van Ness KP (1984) Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 137:380–388

    CAS  PubMed  Google Scholar 

  19. Black D, Duncan A, Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ionpaired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197–203

    CAS  PubMed  Google Scholar 

  20. Eyre DR (1987) Collagen cross-linking amino acids. Meth Enzymol 144:115–139

    CAS  PubMed  Google Scholar 

  21. Knott L, Bailey AJ (1998) Collagen cross-links in mineralizing tissues: A review of their chemistry, function, and clinical relevance. Bone 22:181–187

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Pomeranian Medical University, ul. Powstańców Wielkopolskich 72, 70–111, Szczecin, Poland

    Lidia Ostanek, Iwona Brzosko & Marek Brzosko

  2. Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, ul. Powstańców Wielkopolskich 72, 70–111, Szczecin, Poland

    Andrzej Pawlik, Rozalia Sterna & Barbara Gawrońska-Szklarz

  3. Department of Pharmacology, Pomeranian Medical University, ul. Powstańców Wielkopolskich 72, 70–111, Szczecin, Poland

    Marek Droździk

Authors
  1. Lidia Ostanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrzej Pawlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Iwona Brzosko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marek Brzosko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rozalia Sterna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marek Droździk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Barbara Gawrońska-Szklarz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrzej Pawlik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ostanek, L., Pawlik, A., Brzosko, I. et al. The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab. Clin Rheumatol 23, 214–217 (2004). https://doi.org/10.1007/s10067-003-0856-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-003-0856-5

Keywords

Search

Navigation